Liposomal siRNA nanocarriers for cancer therapy
Top Cited Papers
- 30 December 2013
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 66, 110-116
- https://doi.org/10.1016/j.addr.2013.12.008
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and ChallengesPharmaceuticals, 2013
- RNA-Based Therapeutics: Current Progress and Future ProspectsChemistry & Biology, 2012
- Silencing of p130Cas in Ovarian Carcinoma: A Novel Mechanism for Tumor Cell DeathJNCI Journal of the National Cancer Institute, 2011
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Dicer, Drosha, and Outcomes in Patients with Ovarian CancerNew England Journal of Medicine, 2008
- A combinatorial library of lipid-like materials for delivery of RNAi therapeuticsNature Biotechnology, 2008
- Effect of Interleukin-8 Gene Silencing With Liposome-Encapsulated Small Interfering RNA on Ovarian Cancer Cell GrowthJNCI Journal of the National Cancer Institute, 2008
- Folate receptor alpha as a tumor target in epithelial ovarian cancerGynecologic Oncology, 2008
- Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNAProceedings of the National Academy of Sciences, 2007
- Unlocking the potential of the human genome with RNA interferenceNature, 2004